Emerging Risk Markers; Nitric Oxide and Oxidized Low-Density Lipoprotein in Predicting Coronary Heart Disease in Young subjects
Article Sidebar
-
Coronary Heart Disease, High Density Lipoprotein, Low Density Lipoprotein, Nitric Oxide, Oxidized Low Density Lipoprotein
Abstract
NO is a free radical gas, identified as Endothelial Derived Releasing Factor (EDRF) and synthesized from L-arginine which plays a dynamic role in defence against onset and development of coronary heart disease. Decreased availability of nitric oxide is one of the important cause for the pathogenesis of atherosclerosis. An accumulation of Low Density Lipoprotein cholesterol (LDL) in the intimal wall is the early step in atherosclerosis. Reduced NO level in the endothelium makes it vulnerable and increase the passage of leukocyte and undergo LDL oxidation in the sub endothelial space which ultimately lead to coronary heart disease. The aim of the study is to assess role of Nitric Oxide and oxidized LDL in CHD subjects. This cross-sectional study was conducted in SRM Medical college Hospital and Research centre on subjects attending the Department of Cardiology and Medicine OP. The study was conducted on 194 subjects in age group <40 years and were age and sex matched. After overnight fasting blood samples were collected for analysis for Lipid Profile and Nitric oxide and ox-LDL. Nitric Oxide and ox-LDL measured by ELISA method. Statistical analysis was done using Student ‘t’ test and Pearson correlation analysis for the comparison between two groups. The mean level of Nitric Oxide were decreased (12.97 ± 1.20) significantly in CHD group compared to controls (19.08 ± 4.74) (p <0.001). And Oxidized LDL showed significant increase (41.53 ± 8.72) in CHD group when compared to controls (16.73 ± 3.55) (p<0.001). Reduction in the levels of NO in the arterial wall impairs endothelial function. The study concludes that there is a strong association between NO and ox-LDL in progression of CHD. Interestingly, these analyses can help as diagnostic and monitoring markers in young CHD patients.
Full text article
References
Alique, M., Luna, C., Carracedo, J., Ramirez, R. 2015. LDL biochemical modifications: a link between atherosclerosis and aging. Food & Nutrition Research, 59(1):29240–29240.
Bendall, J. K., Douglas, G., McNeill, E., Channon, K. M., Crabtree, M. J. 2014. Tetrahydrobiopterin in Cardiovascular Health and Disease. Antioxidants & Redox Signaling, 20(18):3040–3077.
Forstermann, U., William.C.Sessa, et al. 2012. Nitric oxide synthases: regulation and function. Eur Heart J, 33(7):829–837.
Gleissner, C. A., Norbert-Leitinger, Klaus-Ley 2007. Effects of Native and Modified Low-Density Lipoproteins on Monocyte Recruitment in Atherosclerosis. Hypertension, 50(2):276–283.
Jing-yi, C., Zi-xin, Y., et al. 2018. Nitric oxide bioavailability dysfunction involves in atherosclerosis. Biomedicine & Pharmacotherapy, 97:423– 428.
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Vm, V., Md, M. 2019. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. 8563845.
Matthys, K. E., Bult, H., et al. 1997. Nitric oxide function in atherosclerosis. Mediators of Inflammation, 6(1):3–21.
Mundi, S., Massaro, M., Scoditti, E., Carluccio, M. A., van Hinsbergh, V. W. M., Iruela-Arispe, M. L., De Caterina, R. 2018. Endothelial permeability, LDL deposition, and cardiovascular risk factors— a review. Cardiovascular Research, 114(1):35–52.
Paoletti, R., Gottojr, A. M., David, P., Hajjar 2004. Inflammation in Atherosclerosis and Implications for Therapy. Circulation, 109(3).
Phaniendra, A., Jestadi, D. B., Periyasamy, L. 2015. Free Radicals: Properties, Sources, Targets, and Their Implication in Various Diseases. Indian J Clin Biochem, 30(1):11–26.
Rader, D. J., Hovingh, G. K., et al. 2014. HDL and cardiovascular disease. The Lancet, 384(9943):618–625.
Rajeev-Gupta, Indu-Mohan, Jagat-Narula 2016. Trends in Coronary Heart Disease Epidemiology in India. Annals of Global Health, 82(2):307–307.
Rajendran, P., Rengarajan, T., Thangavel, J., D, Y. N. 2013. The Vascular Endothelium and Human Diseases. Int J Biol Sci, 9(10):1057–1069.
Richard.O.Cannon, et al. 1998. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clinical Chemistry, 44(8):1809–1819.
Seinosuke-Kawashima, Mitsuhiro-Yokoyama, et al. 2004. Dysfunction of Endothelial Nitric Oxide Synthase and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(6):998–1005.
Singh, R. B., Mengi, S. A., Xu, Y. J., Arneja, A. S., Dhalla, N. S. 2002. Pathogenesis of atherosclerosis: A multifactorial process. Experimental and Clinical Cardiology, 7(1):40–53.
Sozmen, B., Kazaz, C., Taskiran, D., Aslan, L., Akyol, A., Sozmen, E. Y. 2016. Plasma antioxidant status and nitrate levels in patients with hypertension and coronary heart disease. Turkish Journal of Medical Sciences, 28(5):525–532.
Strijdom, H., Chamane, N., Lochner, A. 2009. Nitric oxide in the cardiovascular system: a simple molecule with complex actions. Cardiovascular Journal of Africa, 20(5):303–310.
Witztum, J. L., Steinberg, D., et al. 1991. Role of oxidized low density lipoprotein in atherogenesis. Journal of Clinical Investigation, 88(6):1785–1792.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.